Industry News
Biotechnology Industry News
Exicure’s investigational small…
Exicure’s investigational small molecule succeeded in mobilizing key blood-forming cells in almost 90% of patients in a phase 2 multiple myeloma trial, paving the way for smoother and more effective autologous stem cell transplants.
Ose Immunotherapeutics is…
Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and its ulcerative colitis therapy lusvertikimab.
Pfizer’s recent bidding war for…
Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by this morning’s $1.9 billion biobucks deal.
The FDA is raising the bar for…
The FDA is raising the bar for approval of CAR T-cell therapies in oncology. Under plans outlined by the FDA’s biologics chief Vinay Prasad, M.D., the agency will require developers of many CAR-Ts to show
Novartis has tapped an AI-enabled…
Novartis has tapped an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for immuno-dermatology conditions.
GSK is walking away from Ideaya…
GSK is walking away from Ideaya Biosciences after a five-year-long partnership that initially focused on three of Ideaya's synthetic lethality programs.
Patients with polycythemia vera, a…
Patients with polycythemia vera, a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. But the tide may finally be turning in their favor, as Merck
The drug “has the potential to…
The drug “has the potential to transform the care of those living with DMD amenable to exon 51 skipping,” Dyne CEO John Cox said in a statement.
Dr. Reddy’s Laboratories is…
Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key markets.
With the best-selling medication…
With the best-selling medication in the world in tirzepitide and a record-setting $1 trillion valuation to go with it, Eli Lilly is hardly hurting for cash. But money is only as good as what you
Amid an outpouring obesity data…
Amid an outpouring obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as both companies saw their respective
Mirum Pharmaceuticals is paying…
Mirum Pharmaceuticals is paying $620 million in cash and stock to buy Bluejay Therapeutics and its phase 3-stage hepatitis drug.
A closer look at phase 3 data on…
A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last week is offset by a challenging tolerability profile.
Ascletis Pharma has posted 7.7%…
Ascletis Pharma has posted 7.7% weight loss for the highest dose of its own entrant in the highly contested oral GLP-1 race.
Close to two years after AbbVie…
Close to two years after AbbVie handed over $48 million for the rights to Ose Immunotherapeutics’ inflammation drug, the Big Pharma now wants the French biotech to keep an eye on the asset for a
ORLANDO, Fla.—The leader of…
ORLANDO, Fla.—The leader of Gilead’s Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the company is ready to bring CAR-T to the
ORLANDO, Fla.—With dosing…
ORLANDO, Fla.—With dosing underway in a pivotal phase 3 trial, Star Therapeutics is illuminating the clinical potential of its anti-bleeding antibody VGA039 with encouraging phase 1/2 results in a common bleeding disorder.
Novartis is divulging details from…
Novartis is divulging details from ianalumab’s phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could delay the progression of patients to more serious forms of the disease
The industry’s mRNA alliance is…
The industry’s mRNA alliance is demanding steady FDA leadership, warning that the current “unprecedented turmoil” at the agency is eroding Americans' trust and threatening public health.
The FDA’s reported plan to move…
The FDA’s reported plan to move toward single-trial approvals has stirred industry concern, but one analyst views the proposal as a catalyst for greater R&D investment in the sector.